NCT05142189: Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
- State
- Under way
- Phase
- Phase 1
- People
- 320 planned
- Started
- 17 Jun 2022
- Primary completion
- Feb 2030
- Arms
- Cohort 10: BNT116 + Bispecific Antibody for PD-L1 and VEGF-A (Frail Participants), Cohort 11: BNT116 + Bispecific Antibody for PD-L1 and VEGF-A (After Concurrent CRT)
- Results
- None posted
- 2 Dec 2021: Trial registered
- 17 Jun 2022: Trial started